Stanford University

Halliburton Labs Appoints Pulakesh Mukherjee to Advisory Board

Retrieved on: 
Wednesday, February 28, 2024

Halliburton Labs has announced Pulakesh Mukherjee, Partner, Imperative Ventures has joined its advisory board.

Key Points: 
  • Halliburton Labs has announced Pulakesh Mukherjee, Partner, Imperative Ventures has joined its advisory board.
  • “We are pleased to welcome Pulakesh as we help emerging companies achieve scale and growth,” said Dale Winger, managing director of Halliburton Labs.
  • He serves on numerous industry advisory boards, including the NREL Investor Advisory Board, Activate, and Rocky Mountain Institute.
  • Mukherjee joins Jeff Miller, Reggie DesRoches, John Grotzinger, Jennifer Holmgren, Maynard Holt, Walter Isaacson, and Dale Winger on the Advisory Board.

Saucony® Signs Pro Runner Vanessa Fraser

Retrieved on: 
Friday, March 8, 2024

ROCKFORD, Mich., March 8, 2024 /PRNewswire/ -- Global performance running lifestyle brand Saucony is further solidifying its commitment to elevating women's and girl's participation in running with the signing of pro runner Vanessa Fraser. A seven-time All-American from Stanford University, Fraser, 27, has set personal bests in the 3,000m indoors (8:51); 5,000m indoors (14:48); 10,000m (31:52); and half marathon (1:11:00). Fraser, who turned pro in 2018, is currently based in San Francisco and trains with Team Boss, an elite distance running team located in Boulder, Colorado.

Key Points: 
  • ROCKFORD, Mich., March 8, 2024 /PRNewswire/ -- Global performance running lifestyle brand Saucony is further solidifying its commitment to elevating women's and girl's participation in running with the signing of pro runner Vanessa Fraser.
  • A seven-time All-American from Stanford University, Fraser, 27, has set personal bests in the 3,000m indoors (8:51); 5,000m indoors (14:48); 10,000m (31:52); and half marathon (1:11:00).
  • Fraser, who turned pro in 2018, is currently based in San Francisco and trains with Team Boss, an elite distance running team located in Boulder, Colorado.
  • "Vanessa joins the Saucony roster as a world-class talent with unlimited potential," said Ted FitzPatrick, Saucony's vice president of product and sports marketing.

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

Retrieved on: 
Friday, March 8, 2024

EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis. Each participant will receive a single dose of KYV-101.

Key Points: 
  • "We are grateful for the opportunity to join forces with Kyverna to explore what may prove to be paradigm-changing immunotherapy.".
  • "We are excited about the interest shown by world-class institutions like Stanford to evaluate the clinical performance of KYV-101 in patients suffering from multiple sclerosis," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • CAR T-cell therapy involves modifying a patient's T cells to recognize and remove B cells in the patient's body.
  • Kyverna plans to continue to explore additional indications for KYV-101 and develop a robust pipeline of promising product candidate immunotherapies aimed at addressing unmet medical needs in autoimmune diseases.

OCIF invests in The Knowledge Society to develop the workforce of the future

Retrieved on: 
Wednesday, March 6, 2024

Through the program, students gain real-world exposure, mentorship from industry partners and hands-on opportunities to solve real problems faced by global companies.

Key Points: 
  • Through the program, students gain real-world exposure, mentorship from industry partners and hands-on opportunities to solve real problems faced by global companies.
  • "This investment will have a positive long-term impact as we continue to seek an innovative and diversified economic future for Calgary."
  • OCIF funding will support scholarship resources at TKS, increasing access to the program for students who face financial barriers to participating.
  • This investment will positively impact youth skill development, an enhanced workforce, talent retention and ecosystem development and engagement in Calgary.

2024 Lionel Gelber Prize awarded to Timothy Garton Ash for Homelands: A Personal History of Europe

Retrieved on: 
Wednesday, March 6, 2024

Chosen by a jury of international journalists, practitioners and scholars, the Gelber Prize is awarded annually to the best book on international affairs published in English.

Key Points: 
  • Chosen by a jury of international journalists, practitioners and scholars, the Gelber Prize is awarded annually to the best book on international affairs published in English.
  • Homelands: A personal history of Europe, Timothy Garton Ash (Yale University Press)
    Timothy Garton Ash, Europe's "historian of the present," has been "breathing Europe" for the last half century.
  • The Lionel Gelber Prize was founded in 1989 by Canadian diplomat Lionel Gelber.
  • The award is presented annually by the Lionel Gelber Prize Board and the Munk School of Global Affairs & Public Policy at the University of Toronto.

2024 Lionel Gelber Prize awarded to Timothy Garton Ash for Homelands: A Personal History of Europe

Retrieved on: 
Wednesday, March 6, 2024

TORONTO, March 6, 2024 /PRNewswire/ -- Judith Gelber, Chair of the Lionel Gelber Prize board, announced today that the winner of the 2024 Lionel Gelber Prize is Homelands: A personal history of Europe by Timothy Garton Ash, published by Yale University Press. Chosen by a jury of international journalists, practitioners and scholars, the Gelber Prize is awarded annually to the best book on international affairs published in English. The Prize is presented by the University of Toronto's Munk School of Global Affairs & Public Policy. The winner will receive $50,000.

Key Points: 
  • Chosen by a jury of international journalists, practitioners and scholars, the Gelber Prize is awarded annually to the best book on international affairs published in English.
  • Homelands: A personal history of Europe, Timothy Garton Ash (Yale University Press)
    Timothy Garton Ash, Europe's "historian of the present," has been "breathing Europe" for the last half century.
  • The Lionel Gelber Prize was founded in 1989 by Canadian diplomat Lionel Gelber.
  • The award is presented annually by the Lionel Gelber Prize Board and the Munk School of Global Affairs & Public Policy at the University of Toronto.

Business Plan Contest "Photonics Challenge 2024" was Successfully Held in Hamamatsu City, the Center of the Optical Industry

Retrieved on: 
Wednesday, March 6, 2024

HAMAMATSU, Japan, March 6, 2024 /PRNewswire/ -- Photonics Challenge 2024 is a business contest that supports the expansion of optical technology applications by venture companies and small and medium-sized enterprises (SMEs) nationwide that seek to create new value in society.

Key Points: 
  • Photonics Challenge is an annual competition sponsored by the Graduate University School for the Creation of New Photonics Industries.
  • This year marked its fifth year and is the only business plan contest in Japan that specializes in optical technology.
  • J-Startup Central companies Happy Quality Inc. and ANSeeN Inc. have also been finalists in previous Photonics Challenge competitions.
  • Business Plan focused on the realization of quantitative evaluation and analysis service of biomarkers in hair at higher speed and lower cost than ever before.

Business Plan Contest "Photonics Challenge 2024" was Successfully Held in Hamamatsu City, the Center of the Optical Industry

Retrieved on: 
Wednesday, March 6, 2024

HAMAMATSU, Japan, March 6, 2024 /PRNewswire/ -- Photonics Challenge 2024 is a business contest that supports the expansion of optical technology applications by venture companies and small and medium-sized enterprises (SMEs) nationwide that seek to create new value in society.

Key Points: 
  • Photonics Challenge is an annual competition sponsored by the Graduate University School for the Creation of New Photonics Industries.
  • This year marked its fifth year and is the only business plan contest in Japan that specializes in optical technology.
  • J-Startup Central companies Happy Quality Inc. and ANSeeN Inc. have also been finalists in previous Photonics Challenge competitions.
  • Business Plan focused on the realization of quantitative evaluation and analysis service of biomarkers in hair at higher speed and lower cost than ever before.

Geisinger names Terry Gilliland, MD, as president and future chief executive officer

Retrieved on: 
Monday, March 4, 2024

Dr. Gilliland will become the eighth chief executive officer in Geisinger's 109-year history.

Key Points: 
  • Dr. Gilliland will become the eighth chief executive officer in Geisinger's 109-year history.
  • "On behalf of the entire Board of Directors, I am thrilled to welcome Terry Gilliland to Geisinger," said Heather Acker, chair of the Geisinger Board of Directors.
  • Prior to joining Geisinger, Dr. Gilliland served as chief medical officer and chief science officer at Cogitativo, a healthcare-focused artificial intelligence and machine learning company.
  • Prior to that role, he served as executive vice president of healthcare quality and affordability at Blue Shield of California and senior vice president and chief medical officer of Sentara Healthcare.

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

Retrieved on: 
Monday, March 4, 2024

"We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.

Key Points: 
  • "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.
  • On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies."
  • Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics.
  • Dr. Sandler is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia.